Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study
Estroff J, Devlin J, Hoteit L, Hassoune A, Neal M, Brown J, Lu L, Kotch S, Hazelton J, Christian A, Yeates E, Nahmias J, Jacobson L, Williams J, Schuster K, O'Connor R, Semon G, Straughn A, Cullinane D, Egodage T, Kincaid M, Rollins A, Amdur R, Sarani B. Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study. Journal Of Trauma And Acute Care Surgery 2024, 97: 541-545. PMID: 38685190, DOI: 10.1097/ta.0000000000004345.Peer-Reviewed Original ResearchProthrombin complex concentrateAmount of RBC transfusionRed blood cell transfusionAndexanet alfaRed blood cellsRBC transfusionMulticenter study of adult patientsNon-inferiorityComparing prothrombin complex concentrateOral factor Xa inhibitorsStudy of adult patientsTransfused red blood cellsIncreased RBC transfusionsReversal of DOACsComplex concentrateFactor Xa inhibitorsTreatment of hemorrhageTraumatically injured patientsDOAC reversalMedian transfusionTransfusion rateUnit transfusionsMulticenter studyAdult patientsXa inhibitors